Format

Send to

Choose Destination
  • The following term was not found in PubMed: May;33.
Prenat Diagn. 2013 May;33(5):457-61. doi: 10.1002/pd.4087. Epub 2013 Mar 26.

Maternal serum placental growth factor and α-fetoprotein testing in first trimester screening for Down syndrome.

Author information

1
Biochemistry Department, Royal Victoria Infirmary, Newcastle, UK. kim.donalson@nuth.nhs.uk

Abstract

OBJECTIVE:

The aim of this research was to evaluate the addition of first trimester maternal serum placental growth factor (PlGF) and α-fetoprotein (AFP) to the combined test for Down syndrome and a serum only protocol of PlGF, AFP, free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A.

METHODS:

Samples were from 92 Down syndrome cases with 552 matched controls. All women had a combined test at 11-14 weeks gestation. PlGF and AFP were measured and expressed in multiples of the gestation-specific median (MoM), adjusting for maternal weight and smoking status. Multivariate Gaussian modeling was used to predict detection and false-positive rates.

RESULTS:

The median PlGF level in the cases was 0.694 MoM and controls 1.000 MoM (p = <0.0001). The corresponding values for AFP were 0.764 MoM and 0.990 MoM (p < 0.0001). Statistical modeling predicted that for a given false-positive rate, the addition of PlGF to the combined test increases the detection rate by 4-7%. For a given detection rate, the false-positive rate could be almost halved. When both PlGF and AFP are used, the detection rate increase is 5-8%. A serum only protocol had a predicted a detection rate of 71% for a false-positive rate of 5%.

CONCLUSIONS:

Results suggest a substantial benefit of adding PlGF to the combined test.

PMID:
23529706
DOI:
10.1002/pd.4087
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center